Company overview unavailable
$224.49
+$0.72 (+0.32%)Last close · 2026-09-25
Free AI rating for DHR
See QuantAdvisor's buy/sell/hold call and the reasoning — no account needed.
Price history
Daily closing prices for DHR.
+$31.71 (+16.45%) over the last 3m
Related news
Recent coverage of DHR.

Get the weekly summary of dividend changes for Dividend Champions, Contenders & Challengers, plus upcoming ex-dividend and pay dates.
SeekingAlpha · 1d ago

Opportunities center on automated, standardized TDM kits integrated with AI dosing tools for antimicrobial stewardship, transplant care and precision medicine, especially in Asia-Pacific.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "TDM Reagent Kit Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global TDM Reagent Kit Market, projected to reach USD 2.87 billion in 2026 and grow at a CAGR of 15.84% to USD 6.96 billion
Yahoo · 3d ago

Danaher (DHR) stays a hold: modest core growth and higher leverage after the Masimo acquisition limit upside despite synergies.
SeekingAlpha · 3d ago

Danaher has delivered a 17.4% gain over the past year, which puts a spotlight on one core issue for anyone looking at the stock today: whether the current share price can be explained by the cash flows the business is expected to generate. The 17.4% 1 year return means recent buyers have seen a clear payoff, which raises the question of how much future cash generation is already reflected in the valuation. Recent reports on areas such as label free detection and single use bioreactors...
Yahoo · 3d ago

ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. "Sidharth has a proven track record of building and scaling corporate development functions inside some of the largest healthcare companies in the
Yahoo · 4d ago

Biologics, stricter purity rules and flexible manufacturing are driving demand for single-use, automated and continuous filtration, advanced membranes and sustainable systems.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Pharmaceutical Filtration - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Pharmaceutical Filtration was estimated at US$8.0 Billion in 2025 and is projected to reach US$23.4 Billion by 2032, growing at a CAGR of 16.7% f
Yahoo · 4d ago

Bioreactors Market Gains Momentum as Single-Use Systems, Automation and Advanced Therapies Reshape BiomanufacturingDublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Bioreactors Market Opportunity, Growth Drivers, Industry Trend Analysis and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Bioreactors Market to Reach USD 38.9 Billion by 2035 as Advanced Biomanufacturing Expands The global bioreactors market was valued at USD 13.8 billion in 2025 and is projected to reach
Yahoo · 4d ago

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.
Yahoo · 4d ago
Key statistics
Company fundamentals are temporarily unavailable.
StockTwits chatter
What traders are saying on StockTwits right now
No StockTwits chatter available right now.
Source: StockTwits
Community
Recent posts mentioning DHR.
Sign in to join the QuantAdvisor conversation on DHR — post your take, like and follow.
Data may be delayed. For research, not financial advice.
© 2026 QuantAdvisor. All rights reserved.